Investment Planning in Personalised Medicine

Abstract Personalised cancer therapies are gaining increasing attention due to their demonstrated clinical potential. Nonetheless, such patient-centric, 1:1 business models encompass significant manufacturing and distribution challenges that are directly associated with the patient schedule. In this work we focus on the development and solution of a mixed-integer optimisation problem to suggest cost-efficient candidate networks that guarantee responsiveness and successful delivery of the therapy. The developed model is tested under two demand scenarios, incorporating economies of scale elements.